General procedure for the preparation of HLn (n ؍
2–4). To a
colourless mixture of HL1 and triethylamine (1 equiv.) in THF
was added chlorotrimethylsilane (1 equiv.) dropwise at 0 ЊC. A
white solid began to form during the addition. The mixture was
stirred at this temperature for 1 h, allowed to warm to ambient
temperature and stirred for a further 12 h. A second portion of
triethylamine (1 equiv.) and the appropriate substituted benzyl
bromide (1 equiv.) in THF were added. After heating under
reflux for 18 h, the resulting white solid was filtered off and
discarded. The pale yellow filtrate was concentrated using
a rotary evaporator and the residue was chromatographed on
a silica gel column using CH2Cl2 followed by ethyl acetate as
eluent. The second band was collected and concentrated to give
a colourless liquid.
2-[N-Benzyl-N-(2-mercaptoethyl)]aminomethylpyridine
(HL2). According to the general procedure, HL1 (0.57 g, 3.4
mmol) was stirred with triethylamine (0.47 cm3, 3.4 mmol) and
chlorotrimethylsilane (0.37 g, 3.4 mmol) in THF (40 cm3) for 12
h. Then a second portion of triethylamine (0.47 cm3, 3.4 mmol)
and benzyl bromide (0.58 g, 3.4 mmol) were added, and the
mixture was heated under reflux for 18 h to give HL2 (0.48 g,
55%). 1H NMR (CDCl3): δ 8.51 (d, J = 4.2 Hz, 1 H, PyH), 7.66
(dt, J = 1.8, 7.7 Hz, 1 H, PyH), 7.55 (d, J = 8.1 Hz, 1 H, PyH),
7.22–7.40 (m, 5 H, ArH), 7.15 (t, J = 5.9 Hz, 1 H, PyH), 3.78 (s,
2 H, PyCH2), 3.67 (s, 2 H, ArCH2), 2.73–2.77 (m, 2 H,
NCH2CH2), 2.61–2.68 (m, 2 H, NCH2CH2). 13C{1H} NMR
(CDCl3): δ 159.6, 148.8, 138.8, 136.3, 128.8, 128.2, 127.0,
122.9, 121.9, 59.9, 58.5, 56.7, 22.4. MS (APCI): m/z 259 (15%)
[M ϩ H]ϩ.
[WO2(L1)Cl]. According to the general procedure, [WO2Cl2-
(DME)] (3.32 g, 8.8 mmol) in CH2Cl2 (20 cm3) was treated with
HL1 (1.48 g, 8.8 mmol) and triethylamine (1.2 cm3, 8.8 mmol) in
MeOH (30 cm3) to give [WO2(L1)Cl] (1.14 g, 31%) as a yellow
solid. IR (cmϪ1): 3135m, 2925w, 1607m, 1484w, 1440m, 1340w,
1290m, 1227w, 1157w, 1106w, 1076w, 1025w, 943s ν(WO2),
893s ν(WO2), 819m, 773s, 731m, 645w, 425m. Anal. calc. for
C8H11ClN2O2SW: C, 23.0; H, 2.7; N, 6.7%. Found: C, 22.6; H,
2.9; N, 6.5%.
[WO2(L5)Cl]. According to the general procedure, [WO2Cl2-
(DME)] (1.70 g, 4.5 mmol) in CH2Cl2 (20 cm3) was treated with
HL5 (0.97 g, 4.5 mmol) and triethylamine (0.62 cm3, 4.5 mmol)
in MeOH (30 cm3) to give [WO2(L5)Cl] (0.94 g, 45%) as a grey
solid. IR (cmϪ1): 3055w, 1708w, 1608m, 1585m, 1475m, 1439m,
1297m, 1249w, 1158w, 1083m, 1046m, 997w, 945s ν(WO2),
905s ν(WO2), 814m, 755s, 729m, 681w, 651w. Satisfactory
analytical data for this compound could not be obtained.
General procedure for the preparation of [WO2(Ln)Cl]
(n ؍
2–4). A solution of [WO2Cl2(DME)] in THF was added
dropwise to a solution of HLn (n = 2–4, 1 equiv.) in THF
with vigorous stirring. The pale yellow mixture turned dark
purple immediately. This mixture was stirred at room temper-
ature for 15 min, then triethylamine (1 equiv.) was added, and
the mixture was kept stirring overnight. The resulting mixture
was loaded onto a silica gel column, which was then eluted with
ethyl acetate. The yellow band was collected and concentrated
to give a pale yellow solid.
[WO2(L2)Cl]. According to the general procedure, [WO2Cl2-
(DME)] (0.60 g, 1.6 mmol) was treated with HL2 (0.41 g,
1.6 mmol) and triethylamine (0.22 cm3, 1.6 mmol) in THF
(50 cm3) to give [WO2(L2)Cl] (0.39 g, 48%). 1H NMR (DMSO-
d6): δ 9.23 (d, J = 4.5 Hz, 1 H, PyH), 8.13 (dt, J = 1.8, 7.8 Hz,
1 H, PyH), 7.60–7.69 (m, 4 H, PyH and ArH), 7.46–7.48 (m,
3 H, PyH and ArH), 4.89 (d, J = 14.1 Hz, 1 H, ArCH2), 4.77
(d, J = 15.3 Hz, 1 H, ArCH2), 4.68 (d, J = 14.1 Hz, 1 H, ArCH2),
4.04 (d, J = 15.3 Hz, 1 H, ArCH2), 3.85–3.89 (m, 1 H,
NCH2CH2), 3.56–3.62 (m, 1 H, NCH2CH2), 3.18–3.22 (m, 1 H,
NCH2CH2), 2.26–2.33 (m, 1 H, NCH2CH2). 13C{1H} NMR:
δ 155.5, 150.4, 141.1, 132.5, 132.2, 129.1, 128.8, 125.6, 125.0,
62.3, 61.7, 61.4, 30.2. IR (cmϪ1): 3032w, 2930w, 1608m, 1485w,
1440m, 1421m, 1366w, 1308w, 1294m, 1204w, 1160w, 1047m,
1028m, 951s ν(WO2), 905s ν(WO2), 847w, 783m, 764m, 751m,
723w, 697m, 604w, 546w. HRMS (LSI): m/z calc. for
C15H18ClN2O2SW [M ϩ H]ϩ 509.0287, found 509.0262. Anal.
calc. for C15H17ClN2O2SW: C, 35.4; H, 3.4; N, 5.5%. Found: C,
36.0; H, 3.9; N, 5.3%.
2-[N-(4-tert-Butylbenzyl)-N-(2-mercaptoethyl)]aminometh-
ylpyridine (HL3). According to the general procedure, HL1
(1.23 g, 7.3 mmol) was stirred with triethylamine (1.0 cm3, 7.3
mmol) and chlorotrimethylsilane (0.92 g, 7.3 mmol) in THF
(60 cm3) for 12 h. Then a second portion of triethylamine (1.0
cm3, 7.3 mmol) and 4-tert-butylbenzyl bromide (1.66 g, 7.3
mmol) were added, and the mixture was heated under reflux
for 18 h to give HL3 (0.69 g, 30%). 1H NMR (CDCl3): δ 8.51 (d,
J = 4.2 Hz, 1 H, PyH), 7.67 (dt, J = 1.8, 7.7 Hz, 1 H, PyH), 7.57
(d, J = 7.5 Hz, 1 H, PyH), 7.29–7.36 (m, 4 H, ArH), 7.15 (t,
J = 6.2 Hz, 1 H, PyH), 3.77 (s, 2 H, PyCH2), 3.64 (s, 2 H,
t
ArCH2), 2.63–2.78 (m, 4 H, NCH2CH2), 1.31 (s, 9 H, Bu).
13C{1H} NMR (CDCl3): δ 159.7, 149.9, 148.7, 136.4, 135.5,
128.4, 125.1, 122.9, 121.9, 59.8, 58.0, 56.6, 34.4, 31.3, 22.4. MS
(APCI): m/z 315 (20%) [M ϩ H]ϩ.
2-[N-(3,5-Di-tert-butylbenzyl)-N-(2-mercaptoethyl)]amino-
methylpyridine (HL4). According to the general procedure,
HL1 (0.82 g, 4.9 mmol) was stirred with triethylamine (0.68 cm3,
4.9 mmol) and chlorotrimethylsilane (0.54 g, 4.9 mmol) in THF
(60 cm3) for 12 h. Then a second portion of triethylamine (0.68
cm3, 4.9 mmol) and 3,5-di-tert-butylbenzyl bromide (1.39 g, 4.9
mmol) were added, and the mixture was heated under reflux
for 18 h to give HL4 (0.58 g, 32%). 1H NMR (CDCl3): δ 8.50 (d,
J = 4.5 Hz, 1 H, PyH), 7.65 (dt, J = 1.8, 7.7 Hz, 1 H, PyH), 7.58
(d, J = 7.5 Hz, 1 H, PyH), 7.22–7.29 (m, 3 H, ArH), 7.14 (t, J =
5.3 Hz, 1 H, PyH), 3.77 (s, 2 H, PyCH2), 3.67 (s, 2 H, ArCH2),
[WO2(L3)Cl]. According to the general procedure,
[WO2Cl2(DME)] (0.83 g, 2.2 mmol) was treated with HL3 (0.69
g, 2.2 mmol) and triethylamine (0.30 cm3, 2.2 mmol) in THF
(60 cm3) to give [WO2(L3)Cl] (0.25 g, 20%). 1H NMR (CDCl3):
δ 9.46 (d, J = 5.1 Hz, 1 H, PyH), 7.95 (dt, J = 1.8, 7.8 Hz, 1 H,
PyH), 7.53 (t, J = 6.5 Hz, 1 H, PyH), 7.48 (d, J = 8.7 Hz, 2 H,
ArH), 7.33–7.36 (m, 3 H, PyH and ArH), 4.93 (s, 2 H, ArCH2),
4.89 (d, J = 15.0 Hz, 1 H, PyCH2), 4.07–4.14 (m, 1 H,
NCH2CH2), 3.86 (d, J = 15.0 Hz, 1 H, PyCH2), 3.62–3.70 (m,
1 H, NCH2CH2), 3.30–3.35 (m, 1 H, NCH2CH2), 2.31–2.41 (m,
t
2.67–2.81 (m, 4 H, NCH2CH2), 1.32 (s, 18 H, Bu). 13C{1H}
NMR (CDCl3): δ 159.8, 150.5, 148.7, 137.8, 136.4, 136.2, 123.0,
122.9, 121.9, 120.9, 59.9, 59.1, 56.8, 34.7, 31.5, 22.6. MS
(APCI): m/z 371 (25%) [M ϩ H]ϩ.
t
1 H, NCH2CH2), 1.37 (s, 9 H, Bu). 13C{1H} NMR (CDCl3):
δ 154.8, 152.3, 151.3, 140.1, 131.7, 128.7, 125.8, 125.1, 123.8,
62.9, 61.6, 61.1, 34.7, 31.2, 30.8. IR (cmϪ1): 2960m, 2869m,
1655w, 1609m, 1476m, 1445m, 1365m, 1297m, 1270w, 1218w,
1158w, 1109w, 1077w, 1051w, 1027m, 953s ν(WO2), 910s
ν(WO2), 833m, 815w, 777m, 763w, 726w, 689w, 587w, 557w.
HRMS (LSI): m/z calc. for C19H26ClN2O2SW [M ϩ H]ϩ
565.0913, found 565.0889. Anal. calc. for C19H25ClN2O2SW: C,
40.4; H, 4.5; N, 5.0%. Found: C, 41.0; H, 4.7; N, 4.7%.
General procedure for the preparation of [WO2(Ln)Cl] (n ؍
1,
5). Triethylamine (1 equiv.) was added to a colourless solution
of HLn (n = 1, 5) in MeOH. After stirring at room temperature
for 15 min, the mixture was then transferred to a solution
of [WO2Cl2(DME)] (1 equiv.) in CH2Cl2 via a cannula. This
colourless mixture turned yellow immediately and stirring
was continued overnight. Due to the poor solubility of [WO2-
(Ln)Cl] (n = 1, 5), the resulting solid was collected by filtration,
washed with MeOH, ethyl acetate and hexanes, and dried
in vacuo.
[WO2(L4)Cl]. According to the general procedure,
[WO2Cl2(DME)] (0.60 g, 1.6 mmol) was treated with HL4 (0.59
g, 1.6 mmol) and triethylamine (0.22 cm3, 1.6 mmol) in THF
(60 cm3) to give [WO2(L4)Cl] (0.46 g, 46%). 1H NMR (CDCl3):
J. Chem. Soc., Dalton Trans., 2002, 2366–2370
2367